29/10/2024
|
07:00
|
Final Results for the Year Ended 30 June 2024
|
RNS
|
23/10/2024
|
07:00
|
Notice of Final Results and Investor Presentation
|
RNS
|
21/10/2024
|
07:00
|
Further Subscription to raise £1,000,000
|
RNS
|
11/10/2024
|
07:00
|
Subscription to raise £2,364,000
|
RNS
|
16/09/2024
|
07:00
|
Patent Allowance in China
|
RNS
|
02/09/2024
|
07:00
|
US patent allowance
|
RNS
|
10/07/2024
|
07:00
|
Management Changes
|
RNS
|
01/07/2024
|
07:00
|
Positive Data from SDC-1801 Phase 1 Clinical Trial
|
RNS
|
30/05/2024
|
07:00
|
Appointment of Sole Broker
|
RNS
|
07/05/2024
|
14:10
|
Exercise of Warrants
|
RNS
|
23/04/2024
|
07:00
|
Final Issue of RiverFort Subscription Shares
|
RNS
|
19/04/2024
|
11:35
|
Issue of RiverFort Subscription Shares
|
RNS
|
15/04/2024
|
15:28
|
Issue of RiverFort Subscription Shares
|
RNS
|
09/04/2024
|
16:00
|
Issue of RiverFort Subscription Shares
|
RNS
|
04/04/2024
|
14:38
|
Completion of Equity Fundraise
|
RNS
|
02/04/2024
|
16:51
|
Result of WRAP Retail Offer
|
RNS
|
02/04/2024
|
07:00
|
Increase in size of WRAP Retail Offer
|
RNS
|
28/03/2024
|
07:02
|
WRAP Retail Offer
|
RNS
|
28/03/2024
|
07:01
|
Equity Fundraise
|
RNS
|
28/03/2024
|
07:00
|
Sareum Half-Year Report
|
RNS
|
15/03/2024
|
07:00
|
New Patent Allowance
|
RNS
|
12/03/2024
|
13:30
|
Notice of Interim Results and Trading Update
|
RNS
|
15/02/2024
|
07:00
|
Update on SDC-1801 Clinical Trial Progress
|
RNS
|
02/01/2024
|
07:00
|
Development and commercialisation licence SRA737
|
RNS
|
14/12/2023
|
15:35
|
Results of AGM
|
RNS
|
14/12/2023
|
07:00
|
Annual General Meeting Statement
|
RNS
|
23/11/2023
|
07:00
|
Drawdown of Equity Prepayment Facility
|
RNS
|
21/11/2023
|
07:00
|
Notice of AGM, Annual Report and Accounts
|
RNS
|
09/11/2023
|
07:00
|
Initiation of food effects study for SDC-1801
|
RNS
|
08/11/2023
|
15:03
|
Director Dealings
|
RNS
|
03/11/2023
|
07:05
|
Sareum enhances SDC-1801 patent protection
|
RNS
|
02/11/2023
|
14:48
|
Exercise of Share Options and Director Dealings
|
RNS
|
09/10/2023
|
07:00
|
Final Results for the Year Ended 30 June 2023
|
RNS
|
03/10/2023
|
07:00
|
Notice of Results and Investor Presentation
|
RNS
|
06/09/2023
|
07:00
|
Director's Dealing
|
RNS
|
05/09/2023
|
07:00
|
Director Dealing
|
RNS
|
04/09/2023
|
07:00
|
Dosing of first subjects in MAD Phase 1a trial
|
RNS
|
16/08/2023
|
07:00
|
Update on financial and operational progress
|
RNS
|
03/08/2023
|
07:00
|
Equity Prepayment Facility of up to £5 million
|
RNS
|
26/06/2023
|
07:00
|
Sareum Announces Two New Granted Patents
|
RNS
|
06/06/2023
|
07:00
|
Dosing commences in Phase 1a trial of SDC-801
|
RNS
|
18/05/2023
|
07:00
|
Phase 1a clinical trial for SDC-1801
|
RNS
|
05/05/2023
|
09:20
|
Approval to initiate Phase 1 clinical trial
|
RNS
|
22/03/2023
|
07:00
|
Half-Year Report
|
RNS
|
15/03/2023
|
07:01
|
Update on SDC-1801
|
RNS
|
15/03/2023
|
07:00
|
Notice of Half-Year Results
|
RNS
|
06/03/2023
|
07:00
|
Update on SRA737
|
RNS
|
29/12/2022
|
15:14
|
Director/PDMR Shareholding
|
RNS
|
16/12/2022
|
15:29
|
Results of AGM
|
RNS
|
16/12/2022
|
07:00
|
AGM Statement
|
RNS
|